NAD+ Guide Injections & Precursors

NAD+ became a central longevity molecule for a straightforward reason: every cell spends it. Mitochondria use it to turn food and stored fat into ATP. DNA-repair enzymes spend it during stress. Sirtuins use it to regulate inflammation, circadian timing, and cellular maintenance. How dramatic NAD+ support reads in humans tracks how depleted the pool is and how much demand is on it.

In severe-depletion settings — post-COVID fatigue, chronic illness, alcohol recovery, high training loads — reported improvements in energy, sleep, and cognitive clarity arrive faster on IV and injectable NAD+ than on oral precursors. In healthy populations using NMN or NR as longevity insurance, the signal is slower and quieter: oral precursors raise NAD+ pools, but human lifespan-extension evidence remains thin. A higher number on a lab test is not the same as reversed aging.

The practical case is strongest where depletion is most likely: metabolic support during rapid GLP-1 fat loss (where caloric deficit strains cellular energy production), as the redox currency in the Mito Stack alongside SS-31 and MOTS-c, and for acute recovery after illness or overtraining.

What Is NAD+ and Why Does It Matter?

NAD+ (nicotinamide adenine dinucleotide) is a molecule found in every cell of the body. It’s involved in over 500 biochemical reactions — from converting food into energy, to repairing DNA, to regulating the genes that control aging and stress adaptation.

Most articles describe NAD+ as an "energy molecule." That’s true but incomplete. NAD+ is better understood as cellular currency — a finite resource that multiple critical systems compete for.

The Competing Demands Framework

The NAD+ pool serves four masters simultaneously:

When the NAD+ pool is full, all four systems run smoothly. Energy is steady. Repair happens in the background. Stress resolves. Inflammation completes its work and shuts off.

When the pool is depleted — from chronic stress, poor sleep, illness, or simple aging — the system begins rationing. Energy becomes fragile. Recovery slows. The mechanisms that maintain long-term cellular stability go quiet because they don’t have the fuel to run.

This is why NAD+ depletion doesn’t produce a single symptom. It produces a pattern: fatigue, slow recovery, poor stress tolerance, lingering inflammation, and gradual decline in functions that once ran without notice.

Where NAD+ Declines

"NAD+ falls with age" is the headline claim, and it is too coarse to act on. Where it falls, and in whom, is the part that changes a decision.

What the Compartments Show

You will see "by 60 you’ve lost 50-80% of your NAD+" almost everywhere, usually pointing at one review. That review argues the opposite of what it gets cited for.²¹ It traces the 80% figure to a single small study, calls it the largest such change in the literature by a wide margin, and notes the plasma reports collectively range from no age effect at all to near-total loss. A number that unstable is not a fact to plan around.

What holds up once you separate the compartments:

Two things follow, and they matter more than the headline number:

• Decline is a tissue-and-state property, not a universal age property. It shows up in muscle and in disease. It does not show up reliably in the blood of healthy older adults.
• A blood NAD+ test is close to useless for deciding whether to supplement. If the instrument does not move with the thing you are trying to change, tracking it tells you nothing. Track symptoms under load instead.

None of this means decline is fictional. The mechanisms below are real and well characterized. It means the size of the gap is unknown in any individual, and anyone quoting a precise percentage is quoting a figure the underlying literature does not support.

The CD38 / Senescent Cell Loop

The primary driver of age-related NAD+ decline is immune cells breaking down NAD+ faster than the body can make it. Here’s how the loop works:

1. Old cells accumulate — With age, cells that have stopped dividing but refuse to die (senescent cells¹) build up in tissues.

1. Old cells leak inflammatory signals — These signals tell immune cells to activate, as if fighting an infection that isn’t there.

1. Immune cells ramp up NAD+ destruction — Macrophages exposed to these signals produce 200-300% more of the enzyme that breaks down NAD+ (CD38²).

1. The drain exceeds production — NAD+ is lost faster than the body can make it.

1. The body’s inflammation brakes fail — The enzymes that normally quiet inflammation (sirtuins³) need NAD+ to work. Without it, they go offline.

1. More inflammation → more destruction → lower NAD+ — The loop feeds itself.

This is why the timing of any intervention matters mechanistically: once the spiral has momentum, it is self-reinforcing, and an earlier interruption works against less of it.

Other Factors That Drain NAD+

Beyond the CD38 loop, several factors accelerate NAD+ depletion:

• Constant DNA damage — Under chronic cellular stress (poor sleep, environmental toxins, oxidative load), DNA repair runs 24/7 and burns through NAD+ (PARP overactivation⁴).
• Chronic inflammation — Any inflammatory state increases the enzymes that destroy NAD+.
• Alcohol — Metabolizing alcohol requires NAD+, creating acute depletion.
• Viral illness — SARS-CoV-2 and other viruses trigger multiple NAD+-consuming processes simultaneously.
• Sleep disruption — NAD+ recycling follows circadian patterns. Poor sleep flattens this rhythm (NAMPT regulation⁵).

Foods That Support NAD+ Production

While supplements provide the most direct NAD+ boost, certain foods supply the raw materials for NAD+ synthesis:

Niacin-rich foods (vitamin B3):

• Chicken and turkey breast
• Tuna and salmon
• Peanuts and sunflower seeds
• Mushrooms (especially crimini and portobello)

Tryptophan sources (de novo synthesis):

• Turkey, chicken, eggs
• Dairy products
• Nuts and seeds

Foods with trace NMN:

• Avocado (~0.36-1.6 mg/100g)
• Broccoli (~0.25-1.12 mg/100g)
• Cabbage (~0.0-0.9 mg/100g)
• Beef (~0.06-0.42 mg/100g)
• Edamame (~0.47-1.88 mg/100g)

Reality check: Roughly 100 kg of broccoli matches the NMN in a single 250 mg supplement dose. Diet supports NAD+ maintenance but does not meaningfully restore depleted levels; the supplementation literature addresses that gap.

NAD+ Benefits: What the Research Shows

What the evidence on NAD+ supplementation and therapy supports — organized by strength of evidence rather than marketing claims — breaks down as follows.

Energy and Mitochondrial Function

NAD+ is the electron carrier that makes ATP production possible. When levels are restored:

• ATP production capacity increases
• Mitochondrial efficiency improves
• Oxidative "exhaust" (ROS) decreases

The subjective experience reported isn’t stimulation like caffeine. It reads more like baseline capacity returning to where it used to be — steady energy rather than peaks and crashes.

Evidence: Multiple animal studies show NAD+ precursors improve mitochondrial function and exercise capacity. Human trials show improved muscle metabolism, though subjective energy reports are inconsistent (Elhassan 2019).

Cardiovascular Health

One of the more consistent human findings is cardiovascular benefit:

• NR (1000mg/day) reduced systolic blood pressure by 5-10 mmHg in older adults
• Improved arterial dilation and vascular function
• Enhanced nitric oxide production via SIRT1 activation in endothelium

Evidence: Replicated in multiple trials. Effect size comparable to some lifestyle interventions (Martens 2018).

Metabolic Health

• NMN (250mg/day) improved insulin sensitivity in prediabetic women (Yoshino 2021)
• Improved muscle insulin signaling
• Better glucose handling during exercise

Evidence: Small trials, promising but needs replication. Not all metabolic endpoints improve consistently.

Cognitive Function

The brain is one of the most energy-demanding organs. Low NAD+ means neurons can’t produce enough ATP.

The NADPARK study was the first to demonstrate that oral NR supplementation increases NAD+ in human brain tissue — measured via magnetic resonance spectroscopy, not just blood levels (Brakedal 2024).

Parkinson’s patients showed improvements in some clinical measures, though larger trials are needed.

Evidence: Brain penetration now demonstrated. Clinical benefits still being established. For compounds that use NAD+ to drive neurogenesis directly, see P21.

Sleep and Circadian Rhythm

NAD+ levels naturally oscillate over a 24-hour cycle, regulated by the enzyme NAMPT under circadian clock control. This rhythm helps set the body’s internal clock.

When NAD+ levels are chronically low, this oscillation flattens — disrupting sleep architecture and hormonal rhythms. The SIRT1-NAD+-CLOCK/BMAL1 feedback loop that drives this connection is covered in depth in the circadian reset protocol.

Evidence: Mechanistically clear. Anecdotal reports of improved sleep are common but not yet confirmed in controlled trials.

Inflammation Reduction

NAD+ supplementation has shown anti-inflammatory effects:

• NR reduced IL-6 and TNF-α levels in older adults within weeks
• Improved markers correlate with reduced joint pain in some patients
• Mechanism: NAD+-dependent sirtuins restrain NF-κB inflammatory signaling

Evidence: Biomarker improvements are consistent. Symptom improvements are more variable.

Timeline of Effects

Who’s Researching NAD+?

NAD+ research isn’t fringe or limited to supplement companies. Major academic institutions and federal agencies have dedicated programs.

National Institutes of Health (NIH)

• Federal NAD+ research hub — Studies mitochondrial dysfunction, DNA repair, immune aging, and NAD-dependent stress pathways
• RECOVER Consortium — NIH-led Long COVID program evaluating metabolism, inflammation, and NAD-related mechanisms
• Key researchers: Evandro Fang, Ph.D., Mark Mattson, Ph.D.

Harvard Medical School

• Paul F. Glenn Center for Biology of Aging — Dedicated aging research center
• David Sinclair’s lab has published extensively on age-related NAD+ decline, sirtuin regulation, and NMN research
• Focus: NAD+, neurodegeneration, stress adaptation

Washington University in St. Louis

• Shin-ichiro Imai, M.D., Ph.D. — Studies NAMPT regulation, NAD+ circadian oscillations, and tissue aging
• Discovered eNAMPT (extracellular NAMPT) as a circulating NAD+ regulator
• Core hub for mechanistic NAD+ aging studies

Mayo Clinic

• Eduardo Chini’s lab — Identified CD38 as the major driver of age-related NAD+ decline
• Established the senescent cell → CD38 → NAD+ depletion connection
• Research on NAD+ and cellular senescence

Stanford University

• Center on Longevity — Examines metabolic and immune pathways intersecting with NAD+
• Michael Snyder, Ph.D., has mapped molecular "inflection points" in human aging, including NAD+ pathways
• NAD+ biosynthesis and immune function research

University of Bergen / Haukeland Hospital (Norway)

• NADPARK Study — First randomized controlled trial demonstrating NAD+ augmentation in human brain tissue
• Led by Charalampos Tzoulis, M.D., Ph.D.
• First direct evidence that oral supplementation reaches the brain

University of Iowa

• Charles Brenner, Ph.D. — Discovered nicotinamide riboside (NR) as an NAD+ precursor in 2004
• Foundational work enabling nearly all subsequent NR clinical trials
• Scientific advisor to ChromaDex (Niagen manufacturer)

Active Clinical Trials (U.S.-Based)

Long COVID and NAD+: The Clinical Proof Point

The relationship between NAD+ and Long COVID may be the strongest clinical validation of NAD+ biology to date. The mechanism is clear, and trials are underway.

The Mechanism

SARS-CoV-2 leaves behind a specific metabolic signature: persistent collapse of NAD+ economy within immune, neural, and metabolic tissues.

During acute infection, multiple NAD+-consuming processes activate simultaneously:

1. PARP activation — Viral RNA triggers DNA repair enzymes that burn through NAD+
2. CD38 upregulation — Inflammatory macrophages express more NADase activity
3. Kynurenine pathway diversion — Tryptophan gets diverted away from NAD+ synthesis

The combined result: Sharp, sudden NAD+ depletion. Most patients recover. A subset do not.

The Self-Sustaining Loop

Once NAD+ falls below a critical threshold, the system can’t recover on its own:

• Inflammation brakes fail — The enzymes that quiet inflammatory signaling need NAD+ to work. Without it, the alarm keeps ringing (sirtuin-NF-κB axis⁶).
• New mitochondria stop being built — The signals for mitochondrial growth require NAD+. Production stalls (SIRT3/PGC-1α⁷).
• Daily NAD+ rhythm flattens — NAD+ normally rises and falls with the circadian cycle. That oscillation disappears.
• Each dysfunction reinforces the others — Low NAD+ causes inflammation, which destroys more NAD+.

This is why Long COVID often resembles accelerated aging compressed into months: the same NAD+-driven systems that erode slowly over decades are disrupted abruptly.

Clinical Evidence

• 52% responder rate in a pilot trial (n=36) using NAD+ patches + low-dose naltrexone — promising but needs larger replication
• MGH RECOVER initiative evaluating NAD-related pathways as contributors to persistent symptoms
• Mass General Brigham RCT testing high-dose NR for cognitive recovery and quality of life

A 2022 study directly demonstrated that SARS-CoV-2 suppresses NAMPT and NMNAT — the essential genes for NAD+ salvage — while simultaneously inducing PARP family genes. When NAD+ or NMN was administered, mitochondrial respiration and metabolic coherence improved (Jiang 2022).

Practical Implications

NAD+ restoration for Long COVID is not about treating the infection — it’s about breaking the metabolic trap that sustains dysfunction. Raising the NAD+ floor restores the enabling conditions for other systems to recover.

What Counts as Working

"Did it raise my NAD+?" sounds like one question. It is three, and they come apart.

The first is the level: how much NAD+ sits in blood or tissue. That is what most tests report and most marketing quotes, and it is the weakest of the three. A blood draw is a long way from the muscle or brain in question, the number swings with time of day and last meal, and the molecule is unstable enough in a collection tube that careless handling reads back as a low result.

The second is whether the work gets done — sirtuins running, DNA repair keeping pace, mitochondria producing. This is the reason to raise the level at all, and it does not follow automatically. Six weeks of oral NR in insulin-resistant men raised the NAD+ content of their muscle and changed nothing measurable about insulin sensitivity, mitochondrial function, or body composition (Remie 2020¹⁹). The pool moved; the function did not.

The third applies only to injections: what happens in the minutes afterward, the warmth and flush and chest pressure people describe as the rush. That runs on different machinery, at the outside surface of cells, and it requires no NAD+ to get inside anything (surface signaling¹⁸).

Keeping the three apart is what makes this literature readable. A study can answer one and stay silent on the other two. "Blood NAD+ didn’t move" is an answer to the first question, and it settles neither of the others.

How to Restore NAD+: Injections, IV Therapy, and Supplements

There are three primary approaches to raising NAD+ levels, each with distinct advantages.

Oral Precursors: NMN vs NR

Both NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors — molecules the body converts into NAD+ through natural pathways.

Important note: No head-to-head human trial comparing NR vs NMN exists. Both can raise NAD+ biology. The "fewer steps" argument for NMN is simplified — absorption, digestion, conversion to NR or nicotinamide, and tissue uptake matter as much as the diagram on a label.

Tissue preferences:

What oral supplements show in the data:

• Gradual NAD+ elevation (not immediate)
• Effects typically plateau at 600mg NMN or 1000mg NR — higher doses don’t seem to help more
• Adverse events are limited to mild GI upset at high doses
• Effects plateau at 4-8 weeks (suggesting tissue saturation)

NAD IV Therapy

Intravenous NAD+ bypasses digestion and infuses NAD+ into the bloodstream under clinical supervision.

Key pharmacokinetic insight (Grant et al. 2019):

When 750mg NAD+ is infused over 6 hours:

• No plasma rise until >2 hours despite continuous infusion
• This indicates rapid tissue uptake during the first 2 hours
• Peak elevation: 398% above baseline at 6 hours
• Metabolites peak: NAM +409%, NMN +472% at 8 hours

Practical implication: IV NAD+ is essentially a slow-release delivery system for nicotinamide and other metabolites. The NAD+ itself is rapidly consumed or converted.

If the blood number is the goal, the precursor beats the parent. Head-to-head in a small crossover at a matched 500 mg dose, IV nicotinamide riboside raised whole-blood NAD+ about 21% at three hours; IV NAD+ raised it less (IV comparison¹⁷). The reason is the same chemistry as above — cells import NR directly, while NAD+ has to be taken apart outside the cell first. The NAD+ arm also ran far longer per session, and symptoms rather than the drip set that pace.

Rate matters more than the total dose. Grant’s 750 mg infused slowly across six hours produced no adverse events in eleven people. Commercial protocols compressing 500 mg into 60–100 minutes run several times faster, and at that speed a retrospective of clinic clients found all six NAD+ patients reporting moderate-to-severe cramping, nausea, chest pressure, or elevated heart rate during the infusion — all of it resolving when the infusion ended. Slowing the drip is the lever.

Typical protocols:

• 500-1000 mg per session, infused over 2-4 hours
• Loading series: 4-5 sessions over 2 weeks
• Side effects if infused too fast: nausea, chest tightness, flushing
• Must be administered in clinical setting

NAD Injections: IM and SC Routes

Intramuscular (IM) and subcutaneous (SC) NAD injections offer a middle ground between oral and IV routes.

IM NAD Injection:

• 50-200 mg per injection
• Commonly 2-3 times weekly during active rebuilds, then weekly for maintenance
• The route most often used at-home for larger or more active support doses
• Slower release than IV, fewer acute symptoms
• Self-administered after initial supervision in most at-home protocols
• Slow administration and dilution matter because NAD+ solutions can sting

SC NAD Injection:

• 50-100 mg per dose; above 100 mg the route is IM, which runs 50-200 mg active
• Anything above 50 mg is split across separate injections rather than given as one shot
• 25 mg is a reasonable first dose to test tolerance before moving to the working range
• Slower shallow-depot exposure, but more sting and local welting than IM at the same volume
• An alternate route rather than a lower-dose route: the total does not drop, the injections get smaller

What the human data covers now. Through 2025 there was no controlled human trial of NAD+ given IM or SC at all — the doses above came from clinic practice and user reports. That changed in 2026. A small double-blind trial — 45 people split across nine arms, so four to six per route on NAD+ itself — gave 100 mg by IM, IV, and SC across three consecutive days and tracked what each route produced (injection-route trial¹⁶). The participants were 40 to 65, overweight, sedentary, and mildly fatigued at entry, which is the population the result describes. The injections were tolerated: everyone finished, and no unexpected serious events appeared. What the trial did not do is measure where the NAD+ went — the blood-NAD+ endpoint was held for a later paper. So tolerability at 100 mg now sits on a trial, how much reaches tissue by these routes is still unmeasured, and the 200 mg end of the range remains practice-derived.

Why NAD+ Injections Burn (And How to Reduce It)

If you’ve injected NAD+ subcutaneously, you already know: it burns. This isn’t technique error or bad product — it’s chemistry.

The cause: NAD+ is inherently acidic. Reconstituted NAD+ has a pH around 3.5–4.0, far below your tissue’s neutral pH of ~7.4. When acidic solution contacts subcutaneous tissue, it triggers immediate pain signaling. The burn typically peaks within 30 seconds and fades over 5–15 minutes.

This is universal. Every NAD+ injection will have some degree of sting. The question is how much, and what reduces it.

Dose-Pain Relationship

Higher concentration = more burn. This is counterintuitive if you’re trying to minimize injection volume, but it’s consistent across user reports:

If you’re experiencing intolerable pain, the first step is reducing dose per injection. Two 50 mg injections usually burn less than one 100 mg injection, even though total dose is the same. This is especially true for SubQ use.

Buffered NAD+ reduces the sting

NAD+ stings mainly because it is acidic, so a higher-pH formulation is what reduces the burn. The preference is to buy a buffered version of NAD+, which is formulated at a higher pH, so source it pre-buffered when it is supplied or prescribed for the product. Reconstitute it with BAC water containing sodium chloride (NaCl) to ease the welting; NaCl helps the osmotic side of the discomfort but does not correct the acidity.

Do not mix your own buffer into the syringe. Home-buffering changes the solution chemistry, there is no pharmacokinetic dataset for buffered at-home NAD+, and a buffered preparation should be used promptly. Buy a buffered product rather than improvising, start with smaller volumes, and assess tolerance.

Injection Site Matters

Not all sites burn equally. Based on community reports from r/NicotinamideRiboside and r/Peptides:

• Love handles (lateral hip): Fat pad absorbs slowly; fewer nerve endings
• Outer thigh: Good for larger volumes
• Abdomen: More vascular; faster uptake but more sting
• Inner arm: Thin tissue; not recommended

Rotate within your preferred zone. Don’t inject the same spot repeatedly — this causes localized irritation and can form persistent lumps.

Technique Factors

• Injection speed: Slow injection (30–60 seconds for 1 mL) distributes the acidic load across more tissue, reducing peak pain
• Temperature: Room temperature solution stings less than cold. Let it sit 10–15 minutes after removing from refrigerator
• Needle gauge: 27–30g is standard for SubQ. Smaller gauge = less tissue trauma but slower injection
• Depth: Deeper SubQ (into fat pad, not just under skin) reduces surface nerve activation

When Burning Is NOT Normal

Typical NAD+ burn fades within 15 minutes. Seek medical attention if:

• Pain persists beyond 30 minutes or intensifies
• Redness spreads beyond the immediate injection site
• You develop hives, facial swelling, or difficulty breathing (allergic reaction)
• Hard lumps persist for more than 7 days
• Fever develops

These suggest either allergic response, infection, or contamination — not normal pH-related discomfort.

IM as Alternative

If SubQ burning is intolerable despite mitigation, consider intramuscular (IM) injection. IM deposits NAD+ into muscle tissue, which is often less reactive than a shallow SubQ depot. For this reason, IM is the preferred at-home route for active NAD+ rebuilds, while SubQ is the acceptable fallback when doses are kept smaller and split.

Route Follows the Job, Not a Potency Ranking

The oral-versus-injection argument is usually framed as weak versus strong. That framing is wrong, and the arithmetic is what settles it.

A 100 mg NAD+ injection carries less usable raw material than a single oral capsule. NAD+ is broken down outside the cell before anything gets in, and only the fragment carrying the vitamin B3 ring can be rebuilt into NAD+ — about 18% of the molecule’s mass. Run the numbers and 100 mg injected carries roughly 18 mg of nicotinamide equivalents.²⁰ A 250 mg NMN capsule carries several times more.

So the needle is not buying more material. It is buying a brief, very high local concentration at the injection site, which is a different event from feeding the salvage pathway. Two tools, two jobs:

• Oral NR or NMN — resupply. Steady input into the pathway that rebuilds the pool. The right tool when the goal is a maintained baseline.
• Injection — an acute event. Its value is the surface signaling that happens in the minutes after, not the material delivered. It earns its place when there is a demand to meet.

Running both is not double-dosing. And if oral precursors are not working, the fix is usually consistency rather than switching to a needle — the pool drifts back during missed days regardless of what else is in the protocol.

How Routes Map to Use Case

Cost Considerations

• Oral NMN/NR: Varies by brand and dose
• IM NAD+: 2-4 injections weekly
• SC NAD+: 50–100 mg per dose, delivered in smaller split injections; IM above 100 mg
• IV NAD+: Clinical setting required
• IV loading (5 sessions): Initial intensive phase

Insurance does not cover NAD+ therapy. IM/SC self-administration also requires supplies and initial clinical training. See the reconstitution guide for preparation details.

Combined Approach (Severe Depletion)

1. Weeks 1-4: IM 50-200 mg 2-3× weekly, or clinic IV loading where depletion is severe and supervision is available
2. During loading: oral NR or NMN runs alongside at a conservative daily dose
3. Weeks 4-8: IM continues 1-2× weekly where the response is clear; otherwise the protocol transitions toward oral maintenance
4. Week 8+: IM 100-250 mg total weekly or as needed, with oral daily maintenance where it adds

For NAD+ vial math, the peptide reconstitution calculator calculates BAC-water volume, concentration, and injection volume from the vial size and target dose.

Does NAD+ Work? Evidence Assessment

Sorted by which instrument produced each finding. A mechanism result and a trial result answer different questions, and neither is a senior version of the other — what matters is knowing which question each one answered.

Measured repeatedly in humans

• NAD+ precursors raise blood NAD+ levels — consistent across all trials
• NR improves blood pressure in older adults (5-10 mmHg reduction)
• No serious adverse events at doses up to 2g/day in any trial reported to date
• NR increases brain NAD+ — demonstrated via MRS in NADPARK study
• Injected NAD+ is tolerated at 100 mg by IM, IV, and SC over three days — the first controlled human test of these routes (2026)

Measured in single or small human trials

• NMN improves insulin sensitivity in prediabetic women
• NAD+ + LDN combination shows 52% responder rate for Long COVID fatigue
• Improved muscle function and exercise capacity in older adults
• Anti-inflammatory effects (reduced IL-6, TNF-α)
• IV NR raises whole-blood NAD+ more than IV NAD+ at a matched dose

Carried by mechanism and animal work

• NAD+ supports the redox pool GLP-1 users spend during fat oxidation and caloric deficit
• CD38 inhibitors preserve NAD+ (animal data)
• Long-term supplementation extends healthspan (mouse lifespan data)
• The acute effect of an injection runs through surface signaling rather than cellular refilling

What we don’t know

• Multi-year safety data — maximum trial duration is ~12 weeks
• Whether blood NAD+ reflects tissue levels — especially brain
• Optimal precursor — no NR vs NMN head-to-head human trial
• How much of an IM or SC dose reaches tissue — the 2026 trial deferred that measurement, and no study has made it since
• Long-term cancer risk — theoretical concern, no signal in trials

On that third-from-last point, "bioavailability" needs a noun attached before it means anything. Bioavailability of intact NAD+ is near zero by any route, because the molecule is taken apart before it enters a cell. Bioavailability of the pieces it becomes — nicotinamide, NR — is high and is what actually feeds the pool. Bioavailability of the effect on a tissue is a third thing again, and nobody has measured it for the injected routes. A single percentage figure covering all three, of the kind that appears in marketing copy, is not describing a measurement anyone made.

Who Responds Best

People most likely to benefit from NAD+ restoration:

• Those with chronic fatigue or post-viral illness
• People over 40 with declining energy
• Those with high inflammation or autoimmune conditions
• People who’ve hit plateaus with other protocols
• Those recovering from injury or illness

People less likely to notice dramatic effects:

• Young, healthy individuals with good NAD+ levels already
• Those whose issues aren’t related to cellular energy or inflammation

NAD+ Safety and Contraindications

Oral Supplements (NMN/NR)

In studies up to 1-2 grams per day, the observed adverse-event profile is limited:

• Most common: mild GI upset at high doses
• No serious adverse events in clinical trials
• No liver toxicity or organ damage observed

IV NAD+

Side effects are rate-dependent (happen if infused too fast):

• Nausea
• Abdominal cramping
• Chest tightness or pressure
• Lightheadedness

These resolve when the infusion slows. No serious adverse events have been reported in medical literature from pure NAD+ infusions — but the cardiovascular load is real, and the evidence base in vulnerable populations is thin. Heart failure, a significant arrhythmia history, and low cardiac reserve are the profiles where IV NAD+ carries the most uncertainty; in those profiles cardiology clearance gates the start, and oral NMN/NR carries a lower load. The injectable route is one path among several, and not the first one against a cardiac history.

Absolute Contraindications

Caution Required

The Cancer Question

NAD+ supports cell growth and DNA repair. Cancer cells also need these things. This creates theoretical concern but no actual signal in human data:

• One mouse study suggested high-dose NR might accelerate existing triple-negative breast cancer spread — but the dose was 6.6x higher than typical human doses, sample sizes were tiny, and statistical significance was p=0.52 (not significant)
• No increased cancer rates in any human NAD+ trial
• Some evidence that NAD+ may actually protect against cancer by improving DNA repair

Where the line sits: active cancer contraindicates NAD+ supplementation; a prior cancer history routes through an oncologist before any use.

FAQ

NAD+ and Peptide Integration

For those using peptide therapies, NAD+ provides the foundational capacity that allows peptides to execute their instructions.

Why Peptides Need NAD+

Peptides are signaling molecules — they tell cells what to do. But execution requires energy:

• GLP-1 agonists (semaglutide, tirzepatide, retatrutide) create a deficit and push the body to use stored fuel. NAD+ is required for the redox steps that turn mobilized fat into ATP. Without enough NAD+ capacity, fat can be released but oxidation feels fragile. Injectable L-Carnitine is the transport partner, shuttling fatty acids into mitochondria where NAD+ supports the burn. Learn more about GLP-1 therapy →

• Healing peptides (BPC-157, TB-500) signal repair, but repair is energy-intensive. Without NAD+, signals arrive but execution falters. NAD+ and healing →

• Anti-aging peptides activate maintenance programs that depend on sirtuins — which require NAD+ to function. NAD+ and aging →

• Mitochondrial peptides (SS-31, MOTS-c) improve energy machinery, but machinery needs NAD+ to run. The MITT Stack →

For the two-component timing and dosing question without SS-31, see the NAD+ and MOTS-c protocol.

High-signal interventions on a depleted base produce partial, fragile improvements. On a repleted base, they produce durable change.

Related Topics

• Mitochondrial Stack White Paper — mitochondrial support peptides, including NAD+ strategies
• SS-31 Guide — cardiolipin-stabilizing peptide that protects mitochondrial membrane function
• MOTS-c Guide — mitochondrial-encoded peptide that coordinates cellular energy metabolism
• NAD+ and MOTS-c Protocol — two-component relationship, timing, and dosing
• Pinealon Guide — neuroprotective tripeptide that supports cognitive function and circadian regulation
• Mitochondrial peptides + GLP-1 — how to combine NAD+ restoration with metabolic peptides
• Why GLP-1 Medications Make You Tired — NAD+ depletion is a key driver of the months 3-6 fatigue wall
• TB-500 Guide — Repair peptide whose healing work is energy-intensive — needs NAD+
• Immune Peptide Protocol — NAD+ is the Phase 1 foundation for immune reconstitution
• Injury Recovery Protocol — NAD+ fuels the cellular energy every repair process runs on
• Where to Inject Peptides — NAD+ injection routes, why it burns, and how to fix it

References

Mechanism Glossary

Term definitions, not citations. Numbered references are in Sources below.

• Senescent cells — Cells that have exited the cell cycle but resist apoptosis; accumulate with age and secrete pro-inflammatory factors (SASP): Covarrubias 2020

• CD38 — NADase enzyme on immune cells; primary driver of age-related NAD+ decline; upregulated by inflammatory cytokines: Camacho-Pereira 2016

• Sirtuins — NAD+-dependent deacetylases (SIRT1-7); regulate metabolism, stress response, and inflammation; restrain NF-κB signaling: Yoshino 2021

• PARP overactivation — Poly(ADP-ribose) polymerase enzymes consume NAD+ during DNA repair; chronic activation depletes pools: Covarrubias 2020

• NAMPT regulation — Nicotinamide phosphoribosyltransferase; rate-limiting enzyme in NAD+ salvage pathway; circadian-regulated: Yoshino 2021

• Sirtuin-NF-κB axis — SIRT1 deacetylates NF-κB p65 subunit, suppressing inflammatory gene transcription; NAD+ depletion releases this brake: Covarrubias 2020

• SIRT3/PGC-1α — SIRT3 (mitochondrial sirtuin) and PGC-1α coordinate mitochondrial biogenesis; both require adequate NAD+: Yoshino 2021

Sources

¹ Covarrubias AJ, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology (2020).
² Camacho-Pereira J, et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction. Cell Metabolism (2016).
³ Yoshino J, et al. NAD+ intermediates: The biology and therapeutic potential. Nature Aging (2021).
⁴ Brakedal B, et al. NR increases brain NAD+ in Parkinson’s disease. Nature Communications (2024).
⁵ Yoshino M, et al. NMN increases muscle insulin sensitivity in prediabetic women. Science (2021).
⁶ Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+. Nature Communications (2018).
⁷ Grant R, et al. Pharmacokinetics of intravenous NAD+ in humans. Redox Biology (2019).
⁸ Freeberg KA, et al. NAD+ precursor supplementation: safety considerations. American Journal of Physiology - Endocrinology and Metabolism (2023).
⁹ Elhassan YS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome. Cell Reports (2019).
¹⁰ McReynolds MR, et al. NAD+ decline is causally linked to loss of metabolic health during aging. GeroScience (2022).
¹¹ Jiang C, et al. NAD+/NMN rescue of SARS-CoV-2-induced metabolic dysfunction. Cell Discovery (2022).
¹² Covarrubias AJ, et al. Senescent cells promote tissue NAD+ decline via CD38+ macrophages. Nature Metabolism (2020).
¹⁶ Nkrumah-Elie Y, et al. Preliminary safety analysis of two pilot clinical trials involving injections of nicotinamide riboside chloride. medRxiv (2026). First controlled human administration of NAD+ by the IM and SC routes (NCT06919328); whole-blood NAD+ endpoint deferred to a later report.
¹⁷ Hawkins J, et al. Randomized, placebo-controlled pilot study evaluating acute Niagen+ IV and NAD+ IV in healthy adults. medRxiv (2024). IV NR versus IV NAD+ at matched dose.
¹⁸ Moreschi I, et al. Extracellular NAD+ is an agonist of the human P2Y11 purinergic receptor. Journal of Biological Chemistry (2006). The receptor evidence for surface-level signaling by extracellular NAD+ in human cells.
¹⁹ Remie CME, et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations. American Journal of Clinical Nutrition (2020). Muscle NAD+ metabolome rose; insulin sensitivity and mitochondrial function did not change.

Foundational Reviews

¹³ Covarrubias AJ, Perrone R, et al. "NAD+ metabolism and its roles in cellular processes during ageing." Nat Rev Mol Cell Biol. 2021. PMID 33353981
¹⁴ de Picciotto NE, Gano LB, et al. "Nicotinamide mononucleotide supplementation reverses vascular dysfunction and oxidative stress with aging in mice." Aging Cell. 2016 Jun. PMID 26970090
¹⁵ Verdin E. "NAD+ in aging, metabolism, and neurodegeneration." Science. 2015. PMID 26785480

²⁰ Mass-balance arithmetic — NAD+ (MW 663.43) carries one nicotinamide equivalent (MW 122.12) per molecule; the rest of the molecule is ADP-ribose, 81.6% of the mass, carrying none. 100 mg NAD+ = 150.7 µmol = 18.4 mg of nicotinamide equivalents. Calculated from molecular weights. This is the mass delivered, not the mass absorbed: absorption efficiency is unmeasured for both the injected and the oral route, so the comparison is upper-bound against upper-bound. The direction of the conclusion does not depend on those efficiencies unless injected NAD+ were several-fold better absorbed than oral nicotinamide, which nothing in the record suggests.

²¹ Peluso A, Damgaard MV, Mori MAS, Treebak JT. Age-dependent decline of NAD+ — universal truth or confounded consensus? Nutrients (2021). A skeptical review: plasma reports range from no age effect to near-complete loss; the widely quoted ~80% traces to a visual estimate off a figure in a study of 9 young versus 10 elderly subjects, which the authors flag as an outlier and condition on "if factual."

²² Tretowicz C, et al. Whole-blood NAD+ across seven independent cohorts Nature Metabolism (2026). Whole-blood NAD+ was stable across age and lifestyle interventions using a validated UHPLC-HRMS assay, though it did respond to NR supplementation.

²³ Elhassan YS, et al. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures Cell Reports (2019 Aug 13). Vastus lateralis biopsy measurement in aged human muscle.

²⁴ Pirinen E, et al. Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy Cell Metabolism (2020 Jul 7). Directly measured muscle NAD+ roughly 2-fold lower than matched controls.